Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors.
Patricia P WadowskiJoseph PultarConstantin WeikertBeate EichelbergerBenjamin PanzerKurt HuberIrene M LangRenate KoppensteinerSimon PanzerThomas GremmelPublished in: Research and practice in thrombosis and haemostasis (2019)
Normal platelet aggregation via PAR-1 and PAR-4 is preserved in many patients with adequate P2Y12 inhibition by prasugrel and ticagrelor. The present findings may at least in part explain adverse ischemic events despite potent P2Y12 inhibition.
Keyphrases
- acute coronary syndrome
- percutaneous coronary intervention
- end stage renal disease
- newly diagnosed
- ejection fraction
- antiplatelet therapy
- prognostic factors
- st segment elevation myocardial infarction
- emergency department
- st elevation myocardial infarction
- anti inflammatory
- coronary artery disease
- patient reported outcomes
- subarachnoid hemorrhage
- drug induced